Physicians estimate up to 15% of people who try GLP-1s — the popular class of anti-obesity medications that includes drugs that include Ozempic and Wegovy — lose less than 5% of their body weight, The Wall Street Journal reported April 1.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
